Abstract Cryotherapy is a common technique used in the management of superficial skin lesions, with current advice on the correct timing for freeze–thaw cycles based on nonscientific visual skin appearances. We investigated the effect of cryotherapy on thermal thawing times by creating a porcine skin model in a laboratory setting maintained at normal skin temperature and comparing liquid nitrogen and liquid nitrous oxide. Thermal assessment was performed using a thermal camera attached to an iPhone 11Pro® smartphone. Liquid nitrogen reduced skin temperature to –60 °C after 5 s of application, recovering to 0 °C after 70 s. Liquid nitrous oxide reduced skin temperature to –34.8 °C after 5 s but had a faster recovery to 0 °C after only 20 s. Both cryogens required a thawing period of 5 min to recover to normal skin temperature. We therefore suggest that optimum cellular degradation should allow for 5-min freeze–thaw cryotherapy cycles; a slower thawing period than is in current common practice.

More from our Archive

• DOI: 10.1093/bjd/ljad072 2023

  Malignancy risk in patients with atopic dermatitis: a population-based cohort study

  Joy Wan, Daniel B Shin, Maha N Syed, Katrina Abuabara, Adina R Lemeshow, Zelma C Chiesa Fuxench, Joel M Gelfand

• DOI: 10.1111/myc.13626 2023

  <i>Candida auris</i> from colonisation to candidemia: A four‐year study

  Juan Vicente Mulet Bayona, Nuria Tormo Palop, Carme Salvador García, María del Remedio Guna Serrano, Concepción Gimeno Cardona

• DOI: 10.1111/jocd.15872 2023

  Efficacy of combined treatment with human adipose tissue stem cell‐derived exosome‐containing solution and microneedling for facial skin aging: A 12‐week prospective, randomized, split‐face study

  Gyeong‐Hun Park, Hyuck Hoon Kwon, Joon Seok, Steven Hoseong Yang, Joon Lee, Byung Chul Park, Eun Shin, Kui Young Park

• DOI: 10.1093/bjd/ljad240 2023

  Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

  Stephan Weidinger, Thomas Bieber, Michael J Cork, Adam Reich, Rosamund Wilson, Sonia Quaratino, Marisa Stebegg, Nuala Brennan, Sally Gilbert, John T O’Malley, Ben Porter-Brown

• DOI: 10.1111/iwj.14311 2023

  Preclinical study of diabetic foot ulcers: From pathogenesis to vivo/vitro models and clinical therapeutic transformation

  Yuqing Du, Jie Wang, Weijing Fan, Renyan Huang, Hongfei Wang, Guobin Liu

• DOI: 10.1001/jamadermatol.2023.2008 2023

  Understanding Discordant Perceptions of Disease Severity Between Physicians and Patients With Eczema and Psoriasis Using Structural Equation Modeling

  Valencia Long, Zhaojin Chen, Ruochen Du, Yiong Huak Chan, Yik Weng Yew, Hazel H. Oon, Steven Thng, Nur Qasrina Binte Iskandar Lim, Chris Tan, Nisha Suyien Chandran, Jose M. Valderas, Phillip Phan, Ellie Choi

• DOI: 10.1093/bjd/ljad224 2023

  Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?

  Carlo Alberto Maronese, John R Ingram, Angelo V Marzano

• DOI: 10.1093/sexmed/qfad030 2023

  Self-reported reasons for having difficulty reaching orgasm in men with diverse etiologies

  David L Rowland, Sarah Padilla, Zsuzsanna Kӧvi, Krisztina Hevesi

• DOI: 10.1093/ced/llad227 2023

  ChatGPT and dermatology: friends or foes?

  Luca Potestio, Fabrizio Martora, Alessia Villani, Angelo Ruggiero, Massimiliano Scalvenzi, Matteo Megna

• DOI: 10.1111/pde.15378 2023

  Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the <scp>ALLEGRO</scp> phase 2b/3 randomized, double‐blind, placebo‐controlled trial

  Maria Hordinsky, Adelaide A. Hebert, Melinda Gooderham, Ohsang Kwon, Nikolay Murashkin, Hong Fang, Kazutoshi Harada, Ernest Law, Dalia Wajsbrot, Liza Takiya, Samuel H. Zwillich, Robert Wolk, Helen Tran